ICCnotes

Inherited Cardiac Conditions reference

Open this condition in the interactive app →

Myotonic Dystrophy

Quick Summary

Definition: An autosomal dominant multisystem disorder caused by a nucleotide-repeat expansion (DMPK or CNBP), featuring myotonia, progressive myopathy and prominent cardiac conduction disease and arrhythmia.[1]

  • Prevalence: 1 in 8,000 (most common adult-onset MD), DM1 more severe than DM2[1]
  • Key genes: DMPK (DM1, CTG repeats), CNBP (DM2, CCTG repeats), autosomal dominant with anticipation
  • Hallmark: Myotonia + progressive conduction disease (PR→AV block) + distal weakness + cataracts + SCD risk
  • High-risk markers: HV interval >70ms, PR >240ms, QRS >120ms, syncope, family history SCD, atrial arrhythmias
  • First-line Mx: Annual ECG/Holter, pacemaker for conduction disease (but doesn't prevent SCD), consider ICD if high-risk, avoid antiarrhythmics

Aetiology

Monogenic (Mendelian): 100%, DM1 (DMPK CTG expansion) and DM2 (CNBP CCTG expansion); shows anticipation[1]

Genetics

Inheritance: Autosomal dominant with anticipation, repeat length increases and disease severity worsens in successive generations.[2]

Familial proportion: Nearly 100% of cases are inherited from an affected parent; de novo repeat expansions are extremely rare. First-degree relatives (parent, sibling, child) have a 50% risk of inheriting the mutation. Offspring of affected mothers are at particular risk of the severe congenital form (DM1) due to maternal anticipation.[2]

DM1: DMPK gene (CTG repeat expansion); normal <37 repeats; pathogenic ≥50 repeats

DM2: CNBP gene (CCTG repeat expansion); typically milder cardiac involvement than DM1

Prevalence

Estimated prevalence 1 in 8,000, the most common adult-onset muscular dystrophy worldwide.[1]

DM1 (Steinert disease) is more common and severe than DM2; cardiac disease accounts for approximately 30% of deaths in DM1.[1]

Diagnosis

Confirming the diagnosis: genetic testing, a CTG repeat expansion in DMPK confirms DM1; a CCTG expansion in CNBP (ZNF9) confirms DM2. DM1 carries the greater cardiac (conduction-disease) risk.[1]

Neuromuscular: Myotonia (delayed muscle relaxation), distal weakness, facial weakness

Cardiac (major cause of death):

  • Progressive conduction disease (PR prolongation → AV block)
  • Atrial arrhythmias, ventricular arrhythmias
  • Cardiomyopathy (less common, late feature)
  • Sudden death (even with pacemaker)

Other: Cataracts, endocrinopathy, cognitive impairment

Investigations

ECG: PR prolongation, AV block, QRS widening, atrial arrhythmias, annual minimum[3]

Holter: Annual 24-hour Holter to detect paroxysmal arrhythmias[2]

Echo: Assess LV function (cardiomyopathy is a late feature)

EP study: Consider if syncope or high-risk ECG features, HV interval ≥70ms predicts need for pacemaker[1]

Genetic testing: CTG/CCTG repeat sizing (diagnostic)

Treatments

Cardiac monitoring:

  • Annual ECG minimum (6-monthly if PR >200ms or QRS >120ms)
  • 24h Holter annually

Pacemaker:

  • Standard indications (2nd/3rd degree AV block, symptomatic bradycardia)
  • Consider if HV interval ≥70ms on EP study

ICD: Secondary prevention; primary prevention if high-risk features + cardiomyopathy

Note: Pacemaker does NOT eliminate SCD risk (ventricular arrhythmias still occur)

Complications

  • Progressive conduction disease: PR and QRS prolongation advancing to high-grade AV block and sudden death, which can occur without overt cardiomyopathy and is a major cause of mortality[1]
  • Atrial flutter or fibrillation and ventricular arrhythmia: sudden death can occur even after pacing, hence the ICD versus pacemaker debate
  • Dilated cardiomyopathy and heart failure: less common, and later
  • Anaesthetic and sedation sensitivity: with respiratory compromise

Risk Stratification

Cardiac disease accounts for ~30% deaths (sudden death, heart failure)

Respiratory failure also major cause of death

Follow-up

Based on ESC 2022 Ventricular Arrhythmia guidelines and myotonic dystrophy cardiac data[3][1].

Advanced / complicated = PR/QRS prolongation or other conduction disease, syncope, documented arrhythmia, or a device in situ.

Genotype-positive / phenotype-negative (G+/P−) = a confirmed pathogenic-variant carrier with no overt disease expression yet.

Genotype+ / Phenotype−Uncomplicated / StableAdvanced / Complicated
FrequencyAnnual (monitor for conduction disease)AnnualEvery 6 months
Clinical reviewSymptoms, syncopeSyncope, palpitations, symptomsAs above + device check
ECGAnnual (PR & QRS)Annual 12-lead (PR & QRS trend)Each visit
Holter / ambulatoryPeriodicAnnual (AF, conduction, VT)6-monthly or symptom-directed
EchocardiographyEvery 1–3 yearsEvery 1–3 yearsAnnual
EPS / deviceIf conduction disease emergesConsider if PR/QRS prolongation or syncopeAs indicated

Disclaimer: This table is general guidance based on published guidelines and does not replace clinical judgement. The responsible clinician is accountable for determining the appropriate, individualised follow-up plan for each patient.

Key Points

  • High index of suspicion for conduction disease - can progress rapidly[1]
  • Pacemaker prevents bradycardia death but NOT ventricular arrhythmias[1]
  • Anesthetic risk - avoid depolarizing agents, prolonged recovery[1]
  • Pregnancy: genetic counselling essential (anticipation → more severe in offspring)

References & Review Date

Last reviewed: June 2026

  1. Wahbi K, et al. Incidence and predictors of sudden death in 1388 patients with myotonic dystrophy type 1. Eur Heart J. 2017;38(10):751–758. doi:10.1093/eurheartj/ehw344
  2. Feingold B, et al. Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association. Circulation. 2017;136(13):e200–e231. doi:10.1161/CIR.0000000000000456
  3. Zeppenfeld K, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. doi:10.1093/eurheartj/ehac262